Cookie Consent by Free Privacy Policy website Philips provides update on earlier announced voluntary CPAP, BiPAP and Mechanical Ventilator recall notification
novembre 15, 2021 - Philips

Philips provides update on earlier announced voluntary CPAP, BiPAP and Mechanical Ventilator recall notification

Comunicato Stampa disponibile solo in lingua originale. 

Amsterdam, the Netherlands – On June 14, 2021, Royal Philips’ (NYSE: PHG, AEX: PHIA) subsidiary, #philips Respironics, initiated a voluntary recall notification* for certain sleep and respiratory care products to address identified potential #health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in these devices. Following the substantial ramp-up of its production, service, and repair capacity, the repair and replacement program in the US and several other markets is under way. 

As expected, the US Food and Drug Administration (FDA) recently conducted an inspection of a #philips Respironics manufacturing facility in connection with the recall. On November 12, 2021, the FDA published a list of the observations it provided to #philips Respironics. In accordance with normal practice, #philips Respironics will submit its response to the inspectional findings for review by the FDA. Importantly, an FDA investigator's list of inspection observations does not constitute a final FDA determination of whether any condition is in violation of the Federal Food, Drug, and Cosmetic Act or any of its implementing regulations. Additionally, the FDA has not changed its recommendation to patients and healthcare providers in relation to affected devices.

“In connection with the voluntary recall notification in June of this year, the FDA has recently conducted an inspection of a #philips Respironics manufacturing facility in the US,” said Frans van Houten, CEO of Royal #philips. “We will work closely with the FDA to clarify and follow up on the inspectional findings and its recent requests related to comprehensive testing. Until we have concluded these discussions, we are not able to publicly provide further details on these responses. We remain fully committed to supporting the community of patients who rely on the affected devices, and the physicians and customers who are dedicated to meeting patient needs.” 

Since June 2021, #philips Respironics and certified testing laboratories have been conducting a comprehensive test and research program on the PE-PUR foam to better assess and scope potential patient #health risks, with support from appropriately qualified third-party experts. #philips Respironics plans to make more data available to the relevant competent authorities as soon as possible after completing the assessment of the above mentioned research and tests, which is anticipated to take place in the fourth quarter. 

Separately, #philips Respironics has conducted testing to support the new silicone replacement foam. Silicone foam testing provided by #philips Respironics to the FDA on devices authorized for marketing in the US had demonstrated acceptable results. #philips Respironics continues to coordinate with the FDA and other competent authorities on its testing.

Ti potrebbe interessare anche

ottobre 13, 2023
ottobre 10, 2023
giugno 15, 2023

Comunicato Stampa disponibile solo in lingua originale. Animations, colors, and shapes help to improve poor situational awareness,...

Comunicato Stampa disponibile solo in lingua originale. Two-year #partnership focused on advocacy, education, and raising awarenes...

Comunicato Stampa disponibile solo in lingua originale. The Innovative #health Initiative has awarded a EUR 24 million grant to th...